Micron Technology (02041) officially listed on the Hong Kong Stock Exchange, with three major businesses collaborating to create another benchmark for the Hong Kong stock market's medical device sector.

On September 7, medical equipment IPO Maikedian (02041) officially listed on the Main Board of the Hong Kong Stock Exchange, with Morgan Stanley Asia Limited and Huatai Financial Holdings (Hong Kong) Limited serving as joint sponsors. With a collaborative layout across three core business segmentslife support, minimally invasive intervention, and in vitro diagnosticsthe company is poised to become another benchmark in the Hong Kong stock medical equipment sector. As a global medical device provider, Maikedian can meet the clinical needs of medical institutions, including various clinical departments, wards, and clinics, as well as community health centers, testing institutions, and home care settings. The company offers over 60 types of life support products, 110 types of minimally invasive intervention products, and 150 types of in vitro diagnostic products, covering all clinical scenarios such as ICUs, operating rooms, laboratories, and home care. In China, the companys products have reached over 6,000 hospitals, including approximately 90% of Grade A tertiary hospitals, covering 31 provinces, municipalities, and autonomous regions. From a financial perspective, the company is at a critical juncture of transitioning from losses to profitability. From 2023 to 2025, total revenue is projected to grow from 1.313 billion yuan to 1.619 billion yuan, with a compound annual growth rate of approximately 11%, while gross margin is expected to increase from 49.6% to 53.7%. In 2026, the companys performance improvement is expected to accelerate further. In the first three months, revenue grew by 19.1% year-on-year to 422 million yuan, with adjusted profits reaching 35 million yuan, a significant increase of 132%. At the same time, the companys self-financing capacity has greatly improved; in the first three months of 2026, cash flow from operating activities turned positive year-on-year, with cash and cash equivalents at the end of the period reaching 321 million yuan. The growth logic of the medical device industry is essentially a process of "accumulating strength for a sudden breakthrough," where companies must make long-term, substantial R&D investments to steadily build product and technological barriers. Maikedians listing on the Hong Kong Stock Exchange marks the entry of this platform enterprise, which has been deeply engaged in the medical device field for over a decade, into the capital market. With the synergistic layout of its three business segments, global market coverage, and the professionalism of its team, the company is expected to occupy a significant position in the Hong Kong stock medical equipment sector.